Altimmune (ALT) Operating Leases (2015 - 2026)

Altimmune (ALT) has 7 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 19.75% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 19.75% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 18.33% from the prior year.
• Operating Leases for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
• Over the last five years, Operating Leases for ALT reached as high as $1.5 million in Q2 2024 and fell as low as $44000.0 in Q1 2024.
• Historically, Operating Leases has averaged $1.0 million across 5 years, with a median of $1.2 million in 2025.
• Across the five-year window, Operating Leases tumbled 73.96% in 2023 and surged 2950.0% in 2025, its largest moves.
• Year by year, Operating Leases stood at $672000.0 in 2022, then sank by 73.96% to $175000.0 in 2023, then soared by 701.14% to $1.4 million in 2024, then fell by 18.33% to $1.1 million in 2025, then decreased by 5.94% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.